Company Overview and News

 
[Press] Substantially Higher Gas Production and Sales Revenue for March Quarter for Australia's Po Valley

2018-05-01 oilvoice
Australia's Po Valley Energy Limited, (“Po Valley” or “The Company”) is pleased to provide its Quarterly Activities Report for the period ending 31 March 2018, including substantially higher gas production volumes and gas sales revenue

 
Po Valley Energy emerges from transformation with new focus

2018-04-30 proactiveinvestors.com.au
Po Valley Energy Limited (ASX:PVE) chairman Michael Masterman speaks to Proactive Investors about the company's transformational year, coinciding with the release of Quarterly Reports.

 
[Press] Po Valley Energy Raises $2.5m in Convertible Note Issue

2018-04-27 oilvoice
Po Valley Energy Limited (“PVE” or “the Company”) is pleased to announce it has secured funding of $2.5m through the issue of a convertible note with a conversion price of $0.042 per share and a maturity of 3 years.

 
[Opinion] 81 New Oil and Gas Projects in Europe to Commence Production by 2025, Says GlobalData

2018-04-06 oilvoice
81 new crude and natural gas projects will start operations in Europe between 2018 and 2025. By 2025, the projects will contribute around 1,496 thousand barrels per day (mbd) to global oil production and close to 4.7 billion cubic feet per day (bcfd) to global gas production, according to GlobalData, a leading data and analytics company.

 
Saffron Energy announces update on South East Asia acquisitions

2018-03-01 energyglobal
For full functionality of this site it is necessary to enable JavaScript. Here are the instructions how to enable JavaScript in your web browser.

 
[Press] Australian Gas Producer Po Valley to Retain Overseas Assets After Mutually Withdrawing From Three Way European Merger

2018-03-01 oilvoice
Following the announcement of 23rd January, 2018, the Boards of Po Valley Energy Limited (“Po Valley”) and Saffron Energy Plc (“Saffron”) have reached a mutual agreement to not proceed with the sale of Po Valley Operations Pty Ltd (“PVO”) and its northern Italian gas assets to Saffron for a consideration of 200 million Saffron shares.

 
[Press] Maiden reserves declared for Po Valley's largest gas field project

2018-02-20 oilvoice
Po Valley Energy is pleased to announce that Maiden 2P Reserves of 36.5 bcf of gas have now been declared at the Company's offshore Adriatic development Teodorico gas field, Italy.

 
Po Valley in 3-way energy merger

2018-01-23 businessnews.com.au
Perth-based oil and gas explorer Po Valley Energy has agreed to sell its assets in northern Italy, including the Selva gas field, in a share purchase agreement worth about £12 million ($21 million).

 
Po Valley sells Italian assets

2018-01-23 businessnews.com.au
Perth-based oil and gas explorer Po Valley Energy has agreed to sell its assets in northern Italy, including the Selva gas field, in a share purchase agreement worth about £12 million ($21 million).

 
Prospex Oil and Gas reports significant commercial gas discovery onshore Italy

2018-01-19 worldoil
LONDON -- Prospex Oil and Gas Plc, the AIM quoted investment company, is pleased to announce that it has been advised by the operator Po Valley Energy Limited (PVE) that strong flowrates from testing operations have confirmed a significant commercial gas discovery at the Podere Maiar-1d appraisal/redevelopment well.  Prospex holds a 17% interest in Podere Maiar, which is located on the Podere Gallina Exploration Permit (Podere Gallina) in the Po Valley region of Italy, a proven hydrocarbon province where over 5,000 wells have been drilled historically.

 
[Press] Prospex Oil & Gas: Significant Commercial Gas Discovery Onshore Italy

2018-01-19 oilvoice
Prospex Oil and Gas Plc, the AIM quoted investment company, is pleased to announce that it has been advised by the operator Po Valley Energy Limited (‘PVE') that strong flow rates from testing operations have confirmed a significant commercial gas discovery at the Podere Maiar-1d appraisal/redevelopment well (‘Podere Maiar' or ‘the Well').  Prospex holds a 17% interest in Podere Maiar, which is located on the Podere Gallina Exploration Permit (‘Podere Gallina) in the Po Valley region of Italy, a proven hydrocarbon province where over 5,000 wells have been drilled historically.

 
[Press] Significant Italian Gas Discovery Confirmed for Po Valley

2018-01-19 oilvoice
Strong gas flows on test have confirmed a significant commercial discovery for Australia's Po Valley Energy Limited (“PVE” or the “Company”) at its new Selva gas field in northern Italy.

 
Significant Commercial Gas Discovery Found Onshore Italy

2018-01-19 rigzone
A significant commercial gas discovery has been made at the Selva gas field in northern Italy, Po Valley Energy Limited (PVE) has confirmed.

 
Po Valley Energy surges on commercial gas discovery

2018-01-19 proactiveinvestors.com.au
Po Valley Energy Limited (ASX:PVE) surged 175% to $0.11 after confirming a commercial gas discovery at its new Selva field in northern Italy.

 
Po Valley soars on gas discovery

2018-01-19 businessnews.com.au
Shares in Perth oil and gas explorer Po Valley Energy have skyrocketed today after the company announced a discovery at its Selva gas field in northern Italy.

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

16h - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

16h - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...